Vallance James H, Wilson Peter J, Leese Graham P, McAlpine Ritchie, MacEwen Caroline J, Ellis John D
Department of Ophthalmology, Ninewells Hospital and Medical School, Dundee, UK.
Diabetes Care. 2008 Jun;31(6):1126-31. doi: 10.2337/dc07-1498. Epub 2008 Mar 17.
We aim to correlate the incidence of diabetic retinopathy and maculopathy requiring laser treatment with the control of risk factors in the diabetic population of Tayside, Scotland, for the years 2001-2006.
Retinal laser treatment, retinal screening, and diabetes care databases were linked for calendar years 2001-2006. Primary end points were the numbers of patients undergoing first or any laser treatment for diabetic retinopathy or maculopathy. Mean A1C and blood pressure and retinal screening rates were followed over the study period.
Over 6 years, the number of patients with diabetes in Tayside increased from 9,694 to 15,207 (57% increase). The number of patients receiving laser treatment decreased from 222 to 138 and first laser treatments decreased from 100 (1.03% of diabetic population) to 56 (0.37%). The number of patients with type 2 diabetes treated for maculopathy decreased from 180 in 2001 to 103 in 2006 (43% reduction, P = 0.03). Mean A1C decreased for type 1 and type 2 diabetic populations (P < 0.01) and a reduction in blood pressure was observed in type 2 diabetic patients (P < 0.01). The number of patients attending annual digital photographic retinopathy screening increased from 3,012 to 11,932.
Laser treatment for diabetic maculopathy in type 2 diabetic patients has decreased in Tayside over a six-year period, despite an increased prevalence of diabetes and increased screening effort. We propose that earlier identification of type 2 diabetes and improved risk factor control has reduced the incidence of maculopathy severe enough to require laser treatment.
我们旨在将2001年至2006年期间苏格兰泰赛德地区糖尿病患者中需要激光治疗的糖尿病视网膜病变和黄斑病变的发病率与危险因素的控制情况相关联。
将2001年至2006年历年的视网膜激光治疗、视网膜筛查和糖尿病护理数据库进行关联。主要终点是接受首次或任何糖尿病视网膜病变或黄斑病变激光治疗的患者数量。在研究期间跟踪平均糖化血红蛋白(A1C)、血压和视网膜筛查率。
在6年时间里,泰赛德地区糖尿病患者数量从9694人增加到15207人(增加了57%)。接受激光治疗的患者数量从222人减少到138人,首次激光治疗从100人(占糖尿病患者群体的1.03%)减少到56人(0.37%)。接受黄斑病变治疗的2型糖尿病患者数量从2001年的180人减少到2006年的103人(减少了43%,P = 0.03)。1型和2型糖尿病患者群体的平均A1C下降(P < 0.01),2型糖尿病患者的血压有所降低(P < 0.01)。每年接受数字摄影视网膜病变筛查的患者数量从3012人增加到11932人。
在泰赛德地区,尽管糖尿病患病率上升且筛查力度加大,但在六年时间里,2型糖尿病患者黄斑病变的激光治疗有所减少。我们认为,2型糖尿病更早的识别和危险因素控制的改善降低了严重到需要激光治疗的黄斑病变的发病率。